Archived explainer. For the current picture see today's NVS page.
Why Is NOVARTIS AG ADR (NVS) Stock Up Today?
By the Top Tier Newswire AI Desk · September 2, 2026 at 12:27 AM ET · reviewed against 20 wire stories
NOVARTIS AG ADR (NVS) is up +6.04% in the latest session. Our newswire has captured 20 stories on NVS across 9 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Novartis AG ADR (NVS) shares surged 6.04% to $161.25 in the session, driven by positive results from two late-stage trials of its drug remibrutinib for the treatment of relapsing multiple sclerosis. The Swiss pharmaceutical company reported that the oral BTK inhibitor met its primary endpoints, showing a significant reduction in relapse rates. This development has sparked optimism among investors about the drug’s potential to compete in the MS market.
What Happened
Novartis announced that its remibrutinib drug successfully demonstrated its ability to reduce flare-ups in patients with the most common form of multiple sclerosis. The results from the Phase III trials were highlighted as a key milestone for the company, with some analysts suggesting the drug could outperform existing treatments like Aubagio. The positive data also appears to have overshadowed recent challenges in the BTK inhibitor space, where some competitors have faced setbacks. The stock’s strong performance reflects investor confidence in the drug’s potential to expand Novartis’s growth opportunities in the neurology segment.
What The Data Shows
The stock has moved up 1.0% over the last eight sessions, from $158.98 to $160.54, before today’s sharp rise. The 6.04% gain brought the share price to $161.25, within the 52-week range of $121.57 to $170.46. The company’s fundamentals remain strong, with a market cap of $290.7 billion, a P/E ratio of 23.0, and a net margin of 22.5%. The recent rally also coincided with two fresh 52-week highs reported on September 1, 2026, alongside 15 fresh 52-week lows, indicating mixed market sentiment across the broader tape.
What To Watch
The next key event for Novartis will be its scheduled earnings report, which is expected in the coming weeks. Investors will be watching for further updates on remibrutinib’s regulatory pathway and potential market access. Additionally, the breadth of coverage and analyst commentary surrounding the drug’s prospects will be important to monitor as the stock continues to attract attention.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NVS · Sep 2 session (5-min) · +0.47% vs prior close · updated 8:45 PM ETAI sentiment, last 36h · averaged over 20 stories · 52/100 neutral
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
11d agoMorningstarBULLISH 67Product/PR
Health Care Up on Defensive Bias - Health Care Roundup
Novartis shares rose after the Swiss drugmaker reported positive results from two late-stage trials in the most common form of multiple sclerosis, saying its new pill helped patients experience fewer flare-ups.
11d agoSeeking AlphaBULLISH 73Product/PR
Novartis: Today's Positive Remibrutinib Data Key To Unlocking Growth Plans
Novartis AG's remibrutinib hits the Phase 3 MS endpoint, beating Aubagio amid BTK rival setbacks. Click for this NVS stock update.
11d agoStocktwits NewsNEUTRAL 54Analyst
TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis
TGTX shares opened lower on Tuesday after Novartis said its drug remibrutinib improved multiple sclerosis in late-stage trials.
11d agoWSJNEUTRAL 50General
Health Care Roundup: Market Talk
Gain insight on Novartis, Bangkok Chain Hospital and more in the latest Market Talks covering the health care sector.
11d agoThe FlyBULLISH 58Analyst
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
11d agoTipRanksBULLISH 73Product/PR
Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials
Novartis ($NVS) stock rose about 6% at the time of writing on Tuesday, after the Swiss drugmaker reported positive results from two late-stage trials of remibrutini...
12d agoBarron'sBULLISH 67General
Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths
12d agoMorningstarBULLISH 71Product/PR
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
The Swiss pharmaceutical company said two trials for relapsing multiple sclerosis met their primary goal by showing its drug, known as remibrutinib and marketed as Rhapsido for the skin condition chronic spontaneous urticaria, reduced relapse rates compared to a rival treatment.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →